Cancers · 2021 · 12 citations · 43 references
MedicineMolecular GeneticsOncologyCancer GeneticsCancer PharmacologyMolecular OncologyCancer Stem CellsMetabolic ReprogrammingMetabolic Reprogramming In CancerOncogene MutationsOncogenic Signaling PathwaysVitamin D MetabolismAcute Myeloid Leukemia BiologyAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentBarriersLong-term Remission MaintenanceReceptor-mediated Transcriptional RegulationVitamin D Activation PathwayVitamin D Receptors
Relapses and resistance to therapeutic agents are major barriers in the treatment of acute myeloid leukemia (AML) patients. These unfavorable outcomes emphasize the need for new strategies targeting drug-resistant cells. As IDH mutations are present in the preleukemic stem cells and systematically conserved at relapse, targeting IDH mutant cells could be essential to achieve a long-term remission in the IDH mutant AML subgroup. Here, using a panel of human AML cell lines and primary AML patient specimens harboring IDH mutations, we showed that the production of an oncometabolite (R)-2-HG by IDH mutant enzymes induces vitamin D receptor-related transcriptional changes, priming these AML cells to differentiate with pharmacological doses of ATRA and/or VD. This activation occurs in a CEBPα-dependent manner. Accordingly, our findings illuminate potent and cooperative effects of IDH mutations and the vitamin D receptor pathway on differentiation in AML, revealing a novel therapeutic approach easily transferable/immediately applicable to this subgroup of AML patients.
43
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lü, Patrick S. Ward, Gurpreet S. Kapoor et al. · Nature · 2012 · 2K citations
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.5K citations · Full text
Medicine, Hematology, Oncology +13